(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune’s first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have received prior chemotherapy.
Shares of the company rose about 5% in premarket trading.
The therapy, branded as Tecelra, was approved to treat synovial sarcoma, which most commonly develops in the extremities.
This type of cancer impacts about 1,000 people in the United States each year and most often occurs in adult males in their 30s or younger, according to the FDA.
The company did not immediately respond to a Reuters request seeking information on the therapy’s pricing and availability.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
